Compare Blackstone Inc (BX) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs Citius Pharmaceuticals Inc — how do they compare? Blackstone Inc trades at $146.49 (market cap $113.32B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Blackstone Inc is far larger — about 6050.2× Citius Pharmaceuticals Inc's market cap, and Blackstone Inc pays a 3.69% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BX | CTXR | |
|---|---|---|
Market Cap | $113.32B | $18.73M |
Sector | Financials | Health |
52-Week High | $188.68 | $1.82 |
52-Week Low | $102.12 | $0.48 |
Dividend Yield | 3.69% | — |
Enterprise Value | — | $14.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone Inc. (BX) trades at $137.13, up 2.76% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $12.41 billion in 2025, with a net income margin of 25.85%, while analyst consensus is a Buy with a $144.00 price target. Recent news includes a $16 billion Kuwait oil pipeline deal and the acquisition of a $25.3 billion Australian loan portfolio from HSBC, highlighting strategic expansion.
The outlook for BX is positive, driven by robust earnings growth and strategic acquisitions, but risks include market volatility and sector-specific pressures. Upside potential exists toward the consensus target, though overbought RSI levels near-term may prompt consolidation.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
